drugset / Trial / NCT03426254

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

NCT03426254

RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the safety and efficacy of two forms of Talazoparib therapy (injections subcutaneously Talazoparib and oral form for the treatment in the equivalent therapeutics dose

Timeline

Start
2022-11-10
Primary completion
2023-12-10
Completion
2024-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Talazoparib Small molecule 1 mg Subcutaneous

Indications